Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting?

Table 4 Change of parameters over a follow-up period in three time points according to therapy group

Parameter	Therapy	Baseline		6 mo		1 yr		Two-way repeated measures ANCOVA	F value	P value
		Mean	SD	Mean	SD	Mean	SD
HbA1c	SGLT-2i	7.74	0.78	7.03	0.72	7.09	0.83	Measurement point effect	7.035	0.002
	GLP-1RA	8.03	1.10	7.22	1.00	7.16	0.85	Therapy and measurement point	4.389	0.004
	Simultaneous	8.49	1.34	7.11	0.96	6.96	0.85	Therapy effect	0.432	0.650
FPG	SGLT-2i	7.98	1.40	7.11	2.41	6.84	1.26	Measurement point effect	2.647	0.091
	GLP-1RA	9.90	2.33	7.48	1.67	7.99	1.68	Therapy and measurement point	4.333	0.007
	simultaneous	10.86	3.53	7.53	1.64	7.33	1.31	Therapy effect	4.227	0.020
BMI	SGLT-2i	37.54	3.18	35.92	3.01	35.32	3.05	Measurement point effect	4.867	0.013
	GLP-1RA	38.76	4.60	37.27	4.44	36.80	4.43	Therapy and measurement point	2.123	0.092
	Simultaneous	39.66	5.59	37.22	5.41	36.94	5.42	Therapy effect	1.473	0.234

ANCOVA: Analysis of covariance; BMI: Body mass index; FPG: Fasting plasma glucose; HbA1c: Hemoglobin A1c; SGLT-2i: Sodium/glucose cotransporter-2 inhibitors; GLP-1RA: Glucagon-like-polypeptide-1 receptor agonist; SD: Standard deviation.